FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed pur

## OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Peacock Jonathan M					2. Issuer Name and Ticker or Trading Symbol Bellerophon Therapeutics, Inc. [ BLPH ]					(Ch	telationship ( eck all applic X Directo	cable)	Person(s) to Is		
	LEROPHO	N THERAPEU	*		3. Date of Earliest Transaction (Month/Day/Year) 09/22/2017							Officer below)	(give title	Other below)	specify
184 LIBERTY CORNER ROAD, SUITE 302				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) WARRE	N N.	J	07059										led by More	Reporting Persethan One Rep	
(City)	(S	tate)	(Zip)												
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date				. Transactio ate Month/Day/	Execution Date,		3. 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) (1) (8) (1) (1)			ed (A) or tr. 3, 4 and	5. Amou Securitie Beneficia Owned F Reported	es F ally (I Following (I	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any		Code	ransaction of ode (Instr. Derivative		ive ies ed ed nstr.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$1.12	09/22/2017		A		10,000		(1)	09/21/2027	Common Stock	10,000	\$0	10,000	D	

## **Explanation of Responses:**

1. This option was granted on September 22, 2017. This option vests in three equal annual installments over a three-year period from the date of grant.

## Remarks:

/s/ Jonathan M. Peacock

\*\* Signature of Reporting Person Date

09/26/2017

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.